Skip to main content
Fuji Pharma Co.,Ltd. logo

Fuji Pharma Co.,Ltd. — Investor Relations & Filings

Ticker · 4554 ISIN · JP3816200004 LEI · 529900L1XVCEHVKHAM60 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2024-02-09 Report Publication Anno…
Country JP Japan
Listing T 4554

About Fuji Pharma Co.,Ltd.

https://www.fujipharma.jp/english/ir/

Fuji Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription medical products. The company's primary focus is on women's healthcare, including hormonal preparations for obstetrics and gynecology, alongside curative medicines and in-vitro diagnostics. Its portfolio includes both specialty and generic drugs. In addition to developing its own pharmaceuticals, Fuji Pharma offers extensive contract manufacturing services for a wide variety of dosage forms, such as solids, injections, ointments, creams, and liquids, for domestic and international clients.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is extremely short (583 characters) and contains a table structure typical of a cover page for a Japanese regulatory filing. Key elements include: "【提出書類】確認書" (Filing Document: Confirmation Document), "【根拠条文】金融商品取引法第24条の４の８第１項" (Legal Basis: Article 24-4-8, Paragraph 1 of the Financial Instruments and Exchange Act), and a section confirming the appropriateness of the "四半期報告書" (Quarterly Report) for the period ending December 31, 2023. This structure strongly suggests a document certifying the accuracy of a quarterly report, which falls under the scope of comprehensive periodic financial reporting, specifically for a period shorter than a year (Interim/Quarterly Report). Given the content confirms the accuracy of the Quarterly Report, the most appropriate classification is Interim / Quarterly Report (IR), as it directly relates to the content and certification of that specific report, rather than just announcing its publication (RPA/RNS).
2024-02-09 Japanese
四半期報告書－第60期第1四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, including the balance sheet and income statement for the first quarter of the 60th fiscal year (period ending December 31, 2023). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. Q1 2024
2024-02-09 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and explicitly states in Section 1 ("提出理由") that it is being submitted following the resolution of matters at the "第59期定時株主総会" (59th Annual General Meeting) held on December 20, 2023. Section 2 details the resolutions passed, including dividend allocation and the election of directors and auditors. This content—reporting the results of a shareholder meeting—aligns perfectly with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to an AGM, the primary function here is reporting the *results* of the vote, not presenting the meeting materials (AGM-R) or soliciting votes (PSI).
2023-12-21 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (571 characters) and contains a header section typical of Japanese regulatory filings, specifically mentioning '有価証券報告書' (Annual Securities Report, equivalent to 10-K) and confirming its accuracy ('記載内容の適正性に関する事項' - Matters concerning the appropriateness of the contents of the Annual Securities Report). It is a confirmation document related to the Annual Securities Report for the period ending September 30, 2023, submitted to the Kanto Local Finance Bureau. Since this is a confirmation/attestation document related to the annual filing, and not the full 10-K itself, it falls under a specific regulatory confirmation or general regulatory filing. Given the context of confirming the accuracy of the Annual Securities Report (which is the 10-K equivalent), and the lack of a specific code for 'Annual Report Confirmation', the most appropriate classification is the general 'Regulatory Filings' (RNS) as it is a specific regulatory submission confirming compliance, or potentially 'AR' if it were an audit report, but this is a management confirmation. Given the structure and content (confirmation of the '有価証券報告書' accuracy), RNS is the safest general regulatory fallback, although it is closely related to the 10-K process. However, since it is a specific confirmation document related to the annual filing, and not the full report, RNS is chosen as the best fit among the provided options for a non-standard, short regulatory confirmation. FY 2023
2023-12-21 Japanese
内部統制報告書－第59期(2022/10/01－2023/09/30)
Governance Information Classification · 100% confidence The document contains Japanese text with headers like "【提出書類】 内部統制報告書" (Document Submitted: Internal Control Report) and references to the Financial Instruments and Exchange Act ("金融商品取引法"). It explicitly discusses the assessment of internal controls over financial reporting ("財務報告に係る内部統制の整備及び運用") as of the fiscal year-end (2023年９月30日). This structure and content strongly indicate a formal report on internal controls, which aligns best with the Audit Report / Information category (AR), as it deals with internal controls and assurance standards, even though it is not a traditional external audit report, it is a regulatory filing concerning internal control assessment standards. Comparing with definitions: - 10-K: This is not the full annual report. - AR (Audit Report / Information): This category includes reports on internal or regulatory stress tests and applied accounting principles. An internal control report fits well here as it is a formal assessment of controls. - CGR (Governance Information): While internal controls relate to governance, the specific focus on 'Financial Reporting Internal Control' points more directly to AR. Given the specific nature of the 'Internal Control Report' (内部統制報告書) concerning financial reporting integrity, AR is the most appropriate classification among the provided options.
2023-12-21 Japanese
有価証券報告書－第59期(2022/10/01－2023/09/30)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the header information for the 59th fiscal year (2022-10-01 to 2023-09-30) for Fuji Pharma Co., Ltd., including regulatory filing details, financial indicators, and XBRL tagging data. It is a comprehensive annual financial disclosure, not an announcement or a summary. FY 2023
2023-12-21 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.